Vaccitech Limited
Magdalen Centre
The Oxford Science Park
1 Robert Robinson Avenue
Oxford
OX4 4GA
United Kingdom
Tel: +44-01865-818808
Website: https://www.vaccitech.co.uk/
About Vaccitech Limited
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world.
The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. The management team has decades of experience in the development of vaccine products.
Vaccitech is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications. and is actively developing an internal pipeline of therapeutic candidates.
YEAR FOUNDED:
2016
LEADERSHIP:
Founders: Professor Adrian Hill and Professor Sarah Gilbert
TECHNOLOGY
Please click here for Vaccitech's technology
CAREER:
Please click here for Vaccitech's job opportunities.
29 articles with Vaccitech Limited
-
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
-
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
7/8/2021
Vaccitech plc today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the William Blair Biotech Focus Conference 2021 on Thursday, July 15 at 1 p.m. EDT.
-
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
7/6/2021
Arbutus Biopharma Corporation and Vaccitech plc announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus infection who are already receiving standard-of-care nucleoside reverse transcriptase inhibitor therapy.
-
Vaccitech to Present at the Jefferies Virtual Healthcare Conference
6/1/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.
-
Money on the Move: April 29 – May 4
5/5/2021
April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world. -
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
5/4/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS.
-
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
-
Vaccitech Announces Pricing of Initial Public Offering
4/29/2021
Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS
-
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
-
Money on the Move: March 17-23
3/24/2021
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week. -
Future Planet Invests in Vaccitech’s Series B Financing
3/17/2021
Future Planet Capital has invested in a $168m Series B financing announced by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation.
-
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
-
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
It was a busy week for clinical trial updates. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
BioSpace Global Roundup, June 25
6/25/2020
Biopharma and life sciences companies provide updates on their pipelines and business plans. -
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
4/30/2020
Vaccitech Ltd and the University of Oxford announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
-
BioSpace Global Roundup, March 26
3/26/2020
Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
BioSpace Global Roundup, Dec. 19
12/19/2019
Companies from across the globe provide updates on their business and product pipelines. -
Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
12/18/2019
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.